跳至主要内容
临床试验/NCT01383863
NCT01383863已完成不适用

A Prospective Observational Study Cohort to Assess the Rate of Castration Resistance, Disease Progression and Overall Survival Over a 3-year Period Post-androgen Deprivation Therapy Induction in Patients With Advanced Prostate Cancer Who Have Previously Participated in the Triptocare Study (Http://Clinicaltrials.Gov/ct2/Show/Study/NCT01020448)

Ipsen35 个研究点 分布在 7 个国家目标入组 180 人开始时间: 2011年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Ipsen
入组人数
180
试验地点
35
主要终点
Castration-resistant prostate cancer (CRPC)

研究概览

简要总结

The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with advanced disease.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Have participated and received study treatment in the Triptocare study
  • Be aware of the investigational nature of this observational study cohort and must give written (personally signed and dated) informed consent

排除标准

  • Absence of written informed consent from the patient

结局指标

主要结局

Castration-resistant prostate cancer (CRPC)

时间窗: Over a 3-year period post-androgen deprivation therapy induction

次要结局

  • Serum prostate specific antigen(Over a 3-year period post-androgen deprivation therapy induction)
  • Overall survival(3-years post-androgen deprivation therapy induction)
  • Serum testosterone(Over a 3-year period post-androgen deprivation therapy induction)
  • Disease progression (DP) rate post-androgen deprivation therapy induction(Over a 3-year period post-androgen deprivation therapy induction)

研究者

发起方
Ipsen
申办方类型
Industry
责任方
Sponsor

研究点 (35)

Loading locations...

相似试验